Palisade Bio Inc. (PALI) Announces 3.65M Share Direct Offering at $0.55/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil falls over 4% as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Palisade Bio Announces $2.0 Million Registered Direct Offering
May 6, 2022 8:30 AM EDTCARLSBAD, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the Company or Palisade Bio), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering of 3,646,690 shares of its common stock, at a purchase price of $0.55 per share.
Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.
The closings of the... More
